Susquehanna International Group
CYCN icon

Susquehanna International Group’s Cyclerion Therapeutics CYCN Stock Holding History

Susquehanna International Group’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,259
Closed -$11.7K – 12222
2023
Q1 		$19.6K Buy
2,259
+1,306
+137% +$16.5K ﹤0.01% 12059
2022
Q4 		$12.5K Sell
953
-387
-29% -$4.58K ﹤0.01% 11894
2022
Q3 		$23K Sell
1,340
-258
-16% -$4.43K ﹤0.01% 12548
2022
Q2 		$18K Buy
1,598
+606
+61% +$8.68K ﹤0.01% 12390
2022
Q1 		$22K Sell
992
-404
-29% -$9.73K ﹤0.01% 12597
2021
Q4 		$48K Sell
1,396
-1,370
-50% -$64.7K ﹤0.01% 12566
2021
Q3 		$170K Sell
2,766
-1,243
-31% -$81.3K ﹤0.01% 11664
2021
Q2 		$313K Buy
4,009
+2,627
+190% +$164K ﹤0.01% 10690
2021
Q1 		$77K Buy
1,382
+281
+26% +$21.1K ﹤0.01% 11943
2020
Q4 		$67K Buy
1,101
+562
+104% +$38.3K ﹤0.01% 10664
2020
Q3 		$66K Buy
+539
New +$61.6K ﹤0.01% 10111
2020
Q1 		– Sell
-912
Closed -$50K – 10315
2019
Q4 		$50K Buy
912
+386
+73% +$36K ﹤0.01% 9343
2019
Q3 		$128K Sell
526
-64
-11% -$13.8K ﹤0.01% 9422
2019
Q2 		$135K Buy
+590
New +$167K ﹤0.01% 9446

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
TCP
Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group's CYCN Position: Q2 2023 in Review

Susquehanna International Group sold out of Cyclerion Therapeutics (CYCN) in Q2 2023, closing a stake of 2,259 shares — an estimated $11.7K sold.

Susquehanna International Group first reported a position in CYCN in Q2 2019 and held it in 14 quarters. The position peaked at $313K in Q2 2021. 18 funds tracked by Wall St. Rank hold CYCN as of Q2 2023.

  • Susquehanna International Group reported no remaining Cyclerion Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Susquehanna International Group sold 2,259 Cyclerion Therapeutics shares in Q2 2023, an estimated $11.7K.
  • Susquehanna International Group first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 14 quarters.
  • Susquehanna International Group's Cyclerion Therapeutics position peaked at $313K in Q2 2021.
  • 18 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2023.

Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.